An inhibitor of cyclin-dependent kinase, stress-induced p21 Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis

Hepatology

Volumn 41, Issue 6, 2005, Pages 1262-1271

  Lunz III, John G ^a   Tsuji, Hirokazu ^a   Nozaki, Isao ^a   Murase, Noriko ^a   Demetris, Anthony J ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BILE DUCT LIGATION; BILIARY CIRRHOSIS; CELL PROLIFERATION; CONTROLLED STUDY; HEPATIC ENCEPHALOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER STRUCTURE; MALE; MITOSIS INHIBITION; MOUSE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; WILD TYPE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BILE DUCTS; BIOLOGICAL MARKERS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; HEPATOCYTES; HUMANS; KI-67 ANTIGEN; LIGATION; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MITOSIS; STRESS;

EID: 20044380746     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20709     Document Type: Article

References (50)

1. Delhaye M, Louis H, Degraef C, Le Moine O, Deviere J, Peny MO, et al. Hepatocyte proliferative activity in human liver cirrhosis. J Hepatol 1999; 30:461-471.
2. Shibata M, Watanabe M, Ueno Y, Sadamoto T, Sato G, Yasushi T, et al. Clinicopathological study of proliferating cell nuclear antigen (PCNA) of hepatocytes in primary biliary cirrhosis. J Gastroenterol 1994;29:56-60.
3. Wang VS, Saab S. Liver transplantation in the era of model for end-stage liver disease. Liver Int 2004;24:1-8.
4. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004;4(Suppl 9):114-131.
5. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003;9:12-18.
6. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev 1999;13:1501-1512.
7. Dotto GP. p21 (WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-M56.
8. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C, Crary GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998;16:2141-2150.
9. Ezure T, Sakamoto T, Tsuji H, Lunz JG 3rd, Murase N, Fung JJ, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000;156:1627-1639.
10. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
11. Lunz JG 3rd, Contrucci S, Ruppert K, Murase N, Fung JJ, Starzl TE, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21 (WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001;158:1379-1390.
12. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16:311-320.
13. Nozaki I, Lunz JG 3rd, Specht S, Park JI, Giraud AS, Murase N, et al. Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol 2004;165:1907-1920.
14. Delhaye M, Louis H, Degraef C, Le Moine O, Deviere J, Gulbis B, et al. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. HEPATOLOGY 1996;23:1003-1011.
15. Desmet VJ. Cholestasis: extrahepatic obstruction and secondary biliary cirrhosis. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the Liver. 3rd ed. Edinburgh: Churchill Livingstone, 1994:425-476.
16. Trautwein C, Will M, Kubicka S, Rakemann T, Flemming P, Manns MP. 2-Acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of cyclin E expression. Oncogene 1999;18:6443-6453.
17. Torbenson M, Yang SQ, Liu HZ, Huang J, Gage W, Diehl AM. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol 2002;161:155-161.
18. Koteish A, Yang S, Lin H, Huang J, Diehl AM. Ethanol induces redox-sensitive cell-cycle inhibitors and inhibits liver regeneration after partial hepatectomy. Alcohol Clin Exp Res 2002;26:1710-1718.
19. Sawada N, Kojima T, Obata H, Isomura H, Atsumi S, Sawaki M, et al. Expression of p21(waf-1/cip-1) is significantly induced in the livers of LEC rats with chronic liver injury. Jpn J Cancer Res 1996;87:1102-1105.
20. Timchenko NA, Wilde M, Kosai KI, Heydari A, Bilyeu TA, Finegold MJ, et al. Regenerating livers of old rats contain high levels of C/EBPalpha that correlate with altered expression of cell cycle associated proteins. Nucleic Acids Res 1998;26:3293-3299.
21. Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev 1996;10:245-260.
22. Albrecht JH, Meyer AH, Hu MY. Regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1/Sdi1) gene expression in hepatic regeneration. HEPATOLOGY 1997;25:557-563.
23. Li R, Hannon GJ, Beach D, Stillman B. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 1996;6:189-199.
24. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8:1750-1758.
25. Demetris AJ, Sakamoto T, Liu Z, Yokomuro S, Ezure T, Murase N, et al. The ductular reaction in liver disease emphasis on a type I response. In: Fleig WE, ed. Normal and Malignant Liver Cell Growth. Dordecht: Kluwer Academic Publishers, 1999:141-155.
26. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230.
27. Kaido T, Seto S, Yamaoka S, Yoshikawa A, Imamura M. Perioperative continuous hepatocyte growth factor supply prevents postoperative liver failure in rats with liver cirrhosis. J Surg Res 1998;74:173-178.
28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-1501.
29. Kwon YH, Jovanovic A, Serfas MS, Tyner AL. The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury. J Biol Chem 2003;278:30348-30355.
30. Kinoshita A, Wanibuchi H, Imaoka S, Ogawa M, Masuda C, Morimura K, et al. Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. Carcinogenesis 2002;23:341-349.
31. Huang YT, Hsu YC, Chen CJ, Liu CT, Wei YH. Oxidative-stress-related changes in the livers of bile-duct-ligated rats. J Biomed Sci 2003;10:170-178.
32. Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol 2000;35:927-945.
33. Simpson DM, Beynon RJ, Robertson DH, Loughran MJ, Haywood S. Copper-associated liver disease: a proteomics study of copper challenge in a sheep model. Proteomics 2004;4:524-536.
34. Videla LA, Fernandez V, Tapia G, Varela P. Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals 2003; 16:103-111.
35. Stell DA, McAlister VC, Thorburn D. A comparison of disease severity and survival rates after liver transplantation in the United Kingdom, Canada, and the United States. Liver Transpl 2004;10:898-902.
36. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
37. Crary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. HEPATOLOGY 1998;28:738-743.
38. Kobayashi S, Matsushita K, Saigo K, Urashima T, Asano T, Hayashi H, et al. P21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues. Cancer 2001;91:2096-2103.
39. Wagayama H, Shiraki K, Yamanaka T, Sugimoto K, Ito T, Fujikawa K, et al. p21WAF1/CTP1 expression and hepatitis virus type. Dig Dis Sci 2001; 46:2074-2079.
40. Papakyriakou P, Tzardi M, Valatas V, Kanavaros P, Karydi E, Notas G, et al. Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis 2002;7:133-141.
41. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-429.
42. Weiss RH, Randour CJ. The permissive effect of p21(Waf1/Cip1) on DNA synthesis is dependent on cell type: effect is absent in p53-inactive cells. Cell Signal 2000;12:413-418.
43. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci U S A 2004;101:4003-4008.
44. Barnouin K, Dubuisson ML, Child ES, Fernandez de Mattos S, Glassford J, Medema RH, et al. H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem 2002;277:13761-13770.
45. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, et al. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta 2003;1637:142-150.
46. Martin KR, Barrett JC. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol 2002;21:71-75.
47. Yang S, Koteish A, Lin H, Huang J, Roskams T, Dawson V, et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. HEPATOLOGY 2004;39:403-411.
48. Omori M, Evarts RP, Omori N, Hu Z, Marsden ER, Thorgeirsson SS. Expression of alpha-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats. HEPATOLOGY 1997;25:1115-1122.
49. Demetris AJ, Lunz JG, Subbotin V, Wu T, Nozaki I, Contrucci S, et al. Participation of cytokines and growth factors in biliary epithelial proliferation and mito-inhibition during ductular reactions. In: Alpini G, Alvaro D, Marzioni M, LeSage G, LaRusso NF, eds. The Pathophysiology of Biliary Epithelia. Georgetown, TX: Landes Bioscience, 2003:167-191.
50. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Letizia B, Demetris AJ, et al. Fibrosis correlates with a periportal ductular reaction in chronic hepatitis C: roles of impaired hepatocyte replication, hepatic progenitor cell expansion and steatosis. HEPATOLOGY 2005;41:809-818.